1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow JAK2 Gene Mutation: new trials by email Literature Review of JAK2 Gene Mutation trials Research Report on JAK2 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Ruxolitinib - BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells | Phase 2 | Active not recruiting | Stanford University | 8 | 2019-11-15 | 2026-09-01 |
Eosinophilia (1) · Hepatomegaly (1) · Hypereosinophilic Syndrome (1) · Splenomegaly (1)
Digestive System Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hypertrophy (1) · Leukocyte Disorders (1) · Liver Diseases (1) · Pathological Conditions, Anatomical (1) · Pathological Conditions, Signs and Symptoms (1)
ruxolitinib (1)
United States (1)